REFAMETINIB
Refametinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 6 | 1 | — | — | — | 6 |
| Carcinoma | D002277 | — | C80.0 | — | 3 | — | — | — | 3 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 3 | — | — | — | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 3 | — | — | — | 3 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | REFAMETINIB |
| INN | refametinib |
| Description | Refametinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 923032-36-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1236682 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06309 |
| UNII ID | JPX07AFM0N (ChemIDplus, GSRS) |
Target
Agency Approved
MAP2K1
MAP2K1
MAP2K2
MAP2K2
Organism
Homo sapiens
Gene name
MAP2K1
Gene synonyms
MEK1, PRKMK1
NCBI Gene ID
Protein name
dual specificity mitogen-activated protein kinase kinase 1
Protein synonyms
ERK activator kinase 1, MAPK/ERK kinase 1, MAPKK 1, MEK 1, protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1)
Uniprot ID
Mouse ortholog
Map2k1 (26395)
dual specificity mitogen-activated protein kinase kinase 1 (P31938)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 651 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
30 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use